Advertisement
CRL vs TMO
Which Stock Would AI Choose? Charles River Laboratories (CRL) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- CRL has shown stronger recent momentum with shares up over 20% in the past month, outpacing TMO's approximately 12% gain.
- TMO boasts a significantly larger market capitalization of around $195 billion compared to CRL's $9 billion, reflecting greater scale and diversification.
- Analyst price targets suggest upside potential for both, with CRL averaging around $200 and TMO near $650, indicating relative attractiveness based on current levels.
- Both stocks operate in the life sciences sector but differ in focus: CRL as a contract research organization (CRO) versus TMO's emphasis on instruments and consumables.
- CRL exhibits higher volatility (beta of 1.62) compared to TMO's 0.97, appealing to momentum traders over stability seekers.
- Upcoming quarterly earnings could drive sentiment, with TMO reporting sooner and both facing scrutiny on biotech demand recovery.
Introduction
This stock comparison examines CRL and TMO, two prominent players in the life sciences sector providing essential services and tools for pharmaceutical and biotech research. Investors and traders interested in healthcare innovation, drug development pipelines, and sector rotation amid recovering biotech funding will find value here. As market sentiment shifts with economic conditions and R&D spending trends, understanding their relative performance, business models, and momentum helps assess positioning in the current environment. Both have navigated recent volatility, offering insights into growth drivers and risks for diversified portfolios or targeted trades.
CRL Overview and Recent Performance
Charles River Laboratories International, Inc. (CRL) is a leading global CRO (contract research organization), offering preclinical services like safety assessments, discovery research, and manufacturing support for biopharma clients. In recent market activity, CRL shares have rebounded sharply, climbing over 20% in the past month amid divestitures of non-core units and leadership team refreshes, which boosted investor confidence. Trading around $185 with a market cap of $9.2 billion, the stock remains below its 52-week high of $229 but well above lows near $101, reflecting recovery from prior biotech funding slowdowns. Year-to-date gains stand at about 7%, supported by expectations of preclinical demand resurgence. Sentiment has improved with analyst upgrades and overweight ratings, though negative trailing EPS highlights profitability pressures. Upcoming Q1 earnings on May 7 will test these trends.
TMO Overview and Recent Performance
Thermo Fisher Scientific Inc. (TMO) is a diversified giant in life sciences, supplying analytical instruments, reagents, consumables, software, and services for research, diagnostics, and biopharma production. Shares have gained around 12% in recent weeks, trading near $526 with a massive $195 billion market cap, down from a 52-week high of $644 but up year-to-date by 9%. Performance reflects steady demand in core segments like life sciences solutions, tempered by share price volatility from broader market rotations and price target adjustments. Positive factors include robust revenue of $44.6 billion (TTM) and a P/E ratio (price-to-earnings) of 30, underscoring profitability with 15% margins. Analyst consensus leans buy, with targets around $650. Q1 earnings due April 23 could catalyze further moves amid partnerships in proteomics and data tools.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of the platform's top-performing AI trading bots from over 350 available, each designed to trade thousands of tickers across diverse strategies like trend following, swing trading, and sector-specific plays (e.g., semiconductors, energy, small-caps). Only 25 bots earn a spot here based on current market suitability, displaying impressive stats such as annualized returns up to +168%, win rates ranging from 50% to 88%, and profit factors exceeding 11 in leading examples. These bots vary in timeframes—from short-term signals to longer holds—and risk profiles, providing automated insights for stocks, ETFs, and more. Traders can explore performance history, backtests, and live signals to align with their style; visit the page to discover bots adapting to today's volatile conditions.
Head-to-Head Comparison
CRL and TMO both thrive on biopharma R&D but contrast in scale and model: CRL's service-oriented CRO business ties closely to client pipelines and funding cycles, while TMO's product-heavy portfolio (instruments, consumables) offers recurring revenue stability. Growth drivers differ—CRL benefits from preclinical recovery, TMO from diagnostics and manufacturing scale. Recent momentum favors CRL with sharper gains, but TMO shows steadier YTD performance. Risk profiles highlight trade-offs: CRL's higher beta signals volatility, versus TMO's defensive posture. Sector exposure overlaps in biotech tools, yet sentiment leans positive for both amid analyst optimism, with TMO commanding premium valuation multiples.
Tickeron AI Verdict
Tickeron’s AI currently leans toward CRL in this matchup, driven by superior recent trend consistency, relative undervaluation versus peers, and positioning for biotech rebound catalysts. While TMO offers scale and stability advantages, CRL's momentum and lower entry point suggest higher probabilistic near-term upside in favorable market rotations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRL is a StrongBuy and TMO is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRL’s FA Score shows that 1 FA rating(s) are green whileTMO’s FA Score has 1 green FA rating(s).
- CRL’s FA Score: 1 green, 4 red.
- TMO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRL’s TA Score shows that 7 TA indicator(s) are bullish while TMO’s TA Score has 3 bullish TA indicator(s).
- CRL’s TA Score: 7 bullish, 3 bearish.
- TMO’s TA Score: 3 bullish, 6 bearish.
Price Growth
CRL (@Medical Specialties) experienced а +0.35% price change this week, while TMO (@Medical Specialties) price change was -4.94% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.68%. For the same industry, the average monthly price growth was +13.33%, and the average quarterly price growth was -7.96%.
Reported Earning Dates
CRL is expected to report earnings on Aug 12, 2026.
TMO is expected to report earnings on Jul 29, 2026.
Industries' Descriptions
@Medical Specialties (-3.68% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| CRL | TMO | CRL / TMO | |
| Capitalization | 8.98B | 175B | 5% |
| EBITDA | 291M | 11.7B | 2% |
| Gain YTD | -6.537 | -18.872 | 35% |
| P/E Ratio | 577.05 | 25.82 | 2,235% |
| Revenue | 4.03B | 45.2B | 9% |
| Total Cash | 192M | 3.26B | 6% |
| Total Debt | 3.06B | 43.2B | 7% |
CRL | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 91 Overvalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 94 | |
SMR RATING 1..100 | 94 | 62 | |
PRICE GROWTH RATING 1..100 | 49 | 57 | |
P/E GROWTH RATING 1..100 | 1 | 40 | |
SEASONALITY SCORE 1..100 | n/a | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (12) in the Medical Specialties industry is significantly better than the same rating for CRL (91) in the Miscellaneous Commercial Services industry. This means that TMO’s stock grew significantly faster than CRL’s over the last 12 months.
TMO's Profit vs Risk Rating (94) in the Medical Specialties industry is in the same range as CRL (100) in the Miscellaneous Commercial Services industry. This means that TMO’s stock grew similarly to CRL’s over the last 12 months.
TMO's SMR Rating (62) in the Medical Specialties industry is in the same range as CRL (94) in the Miscellaneous Commercial Services industry. This means that TMO’s stock grew similarly to CRL’s over the last 12 months.
CRL's Price Growth Rating (49) in the Miscellaneous Commercial Services industry is in the same range as TMO (57) in the Medical Specialties industry. This means that CRL’s stock grew similarly to TMO’s over the last 12 months.
CRL's P/E Growth Rating (1) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for TMO (40) in the Medical Specialties industry. This means that CRL’s stock grew somewhat faster than TMO’s over the last 12 months.
| CRL | TMO | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 84% | 4 days ago 47% |
| Stochastic ODDS (%) | 4 days ago 70% | 4 days ago 52% |
| Momentum ODDS (%) | 4 days ago 65% | 4 days ago 62% |
| MACD ODDS (%) | 4 days ago 73% | 4 days ago 68% |
| TrendWeek ODDS (%) | 4 days ago 68% | 4 days ago 61% |
| TrendMonth ODDS (%) | 4 days ago 73% | 4 days ago 62% |
| Advances ODDS (%) | 5 days ago 69% | 8 days ago 62% |
| Declines ODDS (%) | 22 days ago 70% | 6 days ago 63% |
| BollingerBands ODDS (%) | 4 days ago 71% | 4 days ago 52% |
| Aroon ODDS (%) | 4 days ago 60% | 4 days ago 60% |
Advertisement
CRL and
Correlation & Price change
A.I.dvisor indicates that over the last year, CRL has been closely correlated with IQV. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRL jumps, then IQV could also see price increases.